Interactions between Iron dextran and Nu-Iron

The iron polysaccharide in Nu-Iron has a moderate potential interaction with Achlorhydria.

Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions. Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production. Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.

Iron dextran has a moderate potential interaction with Allergies.

Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration. Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma. Epinephrine should be immediately available in the event of acute hypersensitivity reactions.

Iron dextran has a moderate potential interaction with Asthma.

Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration. Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma. Epinephrine should be immediately available in the event of acute hypersensitivity reactions.

Iron dextran has a major potential interaction with Blood Transfusion.

There is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.

The iron polysaccharide in Nu-Iron has a major potential interaction with Blood Transfusion.

There is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.

Iron dextran has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy. Hypotension and flushing have been reported and are thought to be infusion- rate related. Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.

Iron dextran has a major potential interaction with Hemoglobinopathy.

There is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.

The iron polysaccharide in Nu-Iron has a major potential interaction with Hemoglobinopathy.

There is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.

Iron dextran has a major potential interaction with Liver Disease.

Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver. Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes. Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.

Iron dextran has a major potential interaction with Neurological Disorders.

Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness. Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.

The iron polysaccharide in Nu-Iron has a moderate potential interaction with Noninfectious Colitis.

Iron can be irritating and damaging to gastrointestinal mucosa. Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.

The iron polysaccharide in Nu-Iron has a moderate potential interaction with Peptic Ulcer.

Iron can be irritating and damaging to gastrointestinal mucosa. Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.

Iron dextran has a minor potential interaction with Rheumatoid Arthritis.

Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.

Iron dextran has a major potential interaction with Seizures.

Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness. Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.